$CDRE

Cadre Holdings’ (CDRE) Safariland Selected for FBI Ballistic Panel Contract

Cadre Holdings (NYSE:CDRE) said its subsidiary Safariland was selected to supply ballistic panels for an FBI armor contract. Safariland’s SX HP panels will be integrated into Predictive Ballistics’ Overt Armor Kit, after Predictive Ballistics won a five-year, $61 million IDIQ contract for the FBI and other DOJ agencies. The selection followed evaluation versus 11 competitors.

Original reporting
Published Jul 10, 2026, 3:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 3:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cadre Holdings’ (CDRE) Safariland Selected for FBI Ballistic Panel Contract — source image
Decision brief

The 30-second read

$CDREBullishMed
01

Why it matters

If task orders follow, the SX HP panel selection can translate into recurring federal demand and improved visibility for mission-critical protective equipment sales.

02

Market read

Contract selection for ballistic panels under a multi-year FBI IDIQ is a concrete, company-specific catalyst that can drive incremental demand expectations for CDRE.

03

What to watch

The article lacks contract value allocation to Safariland/Cadre, delivery schedule, and whether competitors can win subsequent task orders, which can cap near-term earnings impact.

Relevance 8/10Novelty 7/10Timing: today’s report of Safariland’s selection for an FBI ballistic panel contract

Background

Cadre announced in June that Safariland was selected for an FBI armor contract; the article ties the selection to Predictive Ballistics’ Overt Armor Kit (OAK) and a five-year FBI/DOJ IDIQ.

Company-level read

Ticker impact

$CDREBullishMedium confidence
Context

Cadre’s Safariland subsidiary was selected as the ballistic panel provider for an FBI armor contract, integrating Safariland SX HP panels into OAK.

Expected impact

Likely near-term positive bias as traders price in incremental, multi-year federal procurement exposure; magnitude uncertain without contract revenue allocation details.

Evidence & confidence

The article discloses a specific selection tied to a multi-year FBI IDIQ (five-year, $61 million) and describes competitive evaluation, but it does not quantify Cadre’s share of expected revenue or timing of deliveries.

Market effects

Supports demand visibility for ballistic protection and law-enforcement survivability equipment suppliers, reinforcing the federal procurement pipeline narrative.

Primarily US federal spending exposure; limited direct regional spillover beyond US defense procurement sentiment.

Low global spillover given the article’s focus on US FBI/DOJ procurement and a specific product selection.

Counterpoint

Selection to supply panels under an IDIQ does not guarantee full utilization; actual order volumes and Cadre’s revenue share could be smaller than investors assume.

Key entities

  • Cadre Holdings Inc.

    Parent company of Safariland, selected via its ballistic panel product for an FBI armor contract.

  • Safariland

    Cadre subsidiary selected as the ballistic panel provider for the FBI armor contract.

  • Predictive Ballistics LLC

    Developed the OAK system that integrates Safariland’s SX HP panels.

  • FBI

    Federal agency for the armor contract and IDIQ referenced in the article.

Related articles

$RTXHighAI 9/10

Aerospace and Defense Stocks Q2 Highlights: Cadre (NYSE:CDRE)

Cadre (CDRE) is down 8.4% since its Q2 results. RTX (RTX) reported $24.71B revenue, up 14.5% YoY, beating estimates, and raised its full-year EPS guidance. Its stock is up 13.6%. Ducommun (DCO) reported $224.5M revenue, up 11.8% YoY, also beating estimates. Its stock is up 4.3%. The market has shifted focus from AI to geopolitics and back to fundamentals.

$CDREMedAI 8/10

Cadre Holdings (CDRE) Q2 2026 Earnings Call Transcript

Cadre Holdings (NYSE:CDRE) reported Q2 2026 net sales of $207.1 million, up 32% year over year, and adjusted EBITDA of $42.0 million, up 56%. The company said backlog reached $368 million and raised full-year revenue guidance to $749 million to $769 million and adjusted EBITDA to $139 million to $144 million. It cited an FBI IDIQ contract and Alien Gear acquisition integration.

$CDREHighAI 9/10

Cadre Holdings, Inc. (CDRE): Results of Operations and Financial Condition

Cadre Holdings, Inc. (CDRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cadre Holdings Reports Second Quarter 2026 Financial Results ​ Grew Quarterly Net Sales 32% and Gross Profit 36% Year-Over-Year ​ Increased Quarterly Adjusted EBITDA and Expanded Adjusted EBITDA Margin Both Sequentially and Year-Over-Year ​ Orders Backlog Increases t

$VGMed

12 Best IPO Stocks with Huge Upside Potential

BNN Bloomberg interview (July 6) with Domini Impact Investments’ Maria Llerena said tech was weak into June but H1 was solid, with semiconductors and chips up nearly 90% by end-June. She cited AI-related CapEx concerns, estimating $800B in 2026, and noted a 50% chance of a Fed hike by year-end. The article then lists IPO stocks, including Venture Global (VG) and Cadre (CDRE).

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.